Evidence map›Paper›PMID 41526713›Full record

ArticleApplied microbiology and biotechnology2026

Enhancing stability and safety of chimeric peptidoglycan hydrolases by linker engineering.

Paweł Mitkowski, Elżbieta Jagielska, Małgorzata Korzeniowska Nee Wiweger, Marzena Nowacka, Morten Kjos, Christian Kranjec, Izabela Sabała

Abstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paweł MitkowskiLaboratory of Protein Engineering, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland.
Elżbieta JagielskaLaboratory of Protein Engineering, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland.
Małgorzata Korzeniowska Nee WiwegerLaboratory of Protein Engineering, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland.
Marzena NowackaLaboratory of Protein Engineering, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland.
Morten KjosFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Christian KranjecFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Izabela SabałaLaboratory of Protein Engineering, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland. isabala@imdik.pan.pl.

Funding

EEA Grants/Norway Grants NOR/PONOR/PrevEco/0021/2019Narodowe Centrum Badań i Rozwoju NOR/PONOR/PrevEco/0021/2019
6 · The paper itself

Abstract

Spread of antimicrobial resistance and lack of new antibiotics have brought attention to alternative strategies of combating pathogenic bacteria. One of these strategies takes advantage of the bacteriolytic activity of peptidoglycan hydrolases. The enzymes allow efficient elimination of pathogenic bacteria while preserving the natural microflora. Such enzymes must meet specific criteria of activity, stability, and safety to become efficient enzybiotics. In our previous work (10.1128/spectrum.03546-23), we have created three chimeric enzymes and demonstrated their high efficacy in the elimination of Enterococcus faecalis and Staphylococcus aureus. In this work, we investigated and addressed issues related to the stability and safety of these enzymes. To improve the stability, we engineered the linkers and optimized storage conditions. Moreover, we demonstrated that such enzymes do not have any cytotoxic effects on eukaryotic cells, Danio rerio or Galleria mellonella. We also investigated the prevalence of resistance development, a particularly important feature for new antimicrobials. In conclusion, we here propose efficient, safe, and stable chimeric enzybiotics to eliminate E. faecalis and S. aureus. KEY POINTS: • Optimized linker design enhances enzyme stability. • Generated chimeric lysins do not display cytotoxicity. • Chimeras with minimal risk of resistance development were selected.

Indexed as

Anti-Bacterial AgentsN-Acetylmuramoyl-L-alanine AmidaseProtein EngineeringRecombinant Fusion ProteinsAnimalsEnterococcus faecalisEnzyme StabilityStaphylococcus aureusZebrafishAnti-Bacterial AgentsN-Acetylmuramoyl-L-alanine AmidaseRecombinant Fusion ProteinsBacteriolytic enzymeEnterococcus faecalisLinkerPeptidoglycan hydrolaseProtein engineeringStaphylococcus aureus

Identifiers

PMID41526713
PMCPMC12799751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.